Literature DB >> 1717965

Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate.

H Bonkhoff1, N Wernert, G Dhom, K Remberger.   

Abstract

The relative distribution pattern of the pan-endocrine marker Chromogranin A (Chr A) and the proliferation-associated Ki-67 antigen was investigated in 20 prospectively sampled prostatectomy specimens. In cryostat sections, the Chr A immunoreactivity showed evidence of endocrine differentiation in all 15 prostatic adenocarcinomas. Nine tumors displayed a weak, 5 a moderate, and 1 adenocarcinoma a strong endocrine differentiation. These findings highlight the importance of endocrine differentiation in prostate malignancy that histologically resembles ordinary adenocarcinomas. The simultaneous demonstration of Ki-67 and Chr A revealed that in normal, hyperplastic, and neoplastic prostate tissue Chr A-positive cells were preferentially situated in proximity to Ki-67-labeled cells. This relative distribution pattern of both markers may indicate that endocrine cells are involved in controlling cell proliferation through a paracrine hormonal mechanism. However, an obvious correlation was not found between the degree of endocrine differentiation and proliferative activity in prostatic adenocarcinomas. Furthermore, a coexpression of Ki-67 and Chr A in the same (tumor) cells was not observed suggesting that the endocrine phenotype is only expressed in the G0 phase of the cell cycle as well as in normal, hyperplastic, and neoplastic conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717965     DOI: 10.1002/pros.2990190202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  32 in total

1.  Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.

Authors:  S Zelivianski; J Dean; D Madhavan; F F Lin; M F Lin
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 2.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

3.  Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Authors:  P D Deeble; D J Murphy; S J Parsons; M E Cox
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

4.  LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.

Authors:  Dongxia Ge; Allen C Gao; Qiuyang Zhang; Sen Liu; Yun Xue; Zongbing You
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

Review 5.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

6.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

7.  Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death.

Authors:  M Tarján
Journal:  Indian J Urol       Date:  2010 Jan-Mar

8.  Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates.

Authors:  S Claus; M Wrenger; T Senge; H Schulze
Journal:  Urol Res       Date:  1993

9.  Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.

Authors:  John DaSilva; Daniel Gioeli; Michael J Weber; Sarah J Parsons
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.